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Introduction
Coronary heart disease (CHD) is a leading cause of death and disability worldwide. Angina pectoris appears with a gradual onset after physical or emotional stress and represents a frequent symptom leading to medical consultation. Up to 50% of patients with CHD have intermittent chest pain as the reason for their initial non-acute presentation, requiring referral for outpatient assessment and clinical investigation. As approximately 10% of patients with recent onset angina will suffer from a cardiovascular (CV) event within one year, HYPERLINK \l "_ENREF_1" \o "Gandhi, 1995 #1"  ADDIN EN.CITE <EndNote><Cite><Author>Gandhi</Author><Year>1995</Year><RecNum>1</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="zzaeeswduezsf5ee09rpz0v5259rw0xsdd29" timestamp="1443548795">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Gandhi, Manish M</author><author>Lampe, Fiona C</author><author>Wood, David A</author></authors></contributors><titles><title>Incidence, clinical characteristics, and short-term prognosis of angina pectoris</title><secondary-title>Br Heart J</secondary-title></titles><periodical><full-title>Br Heart J</full-title></periodical><pages>193-198</pages><volume>73</volume><number>2</number><dates><year>1995</year></dates><isbn>1468-201X</isbn><urls></urls></record></Cite></EndNote>1 various diagnostic techniques can be used to identify those patients who may require coronary revascularization. Accurate and prompt CHD diagnosis results in health benefits, but diagnostic techniques also yield false negative and false positive results. False negative diagnoses increase the risk of CV adverse events while false positive diagnoses are associated with elevated mortality due to unnecessary X-ray coronary angiography (CA) and percutaneous coronary intervention (PCI). and exposure to radiation during subsequent single photon emission computed tomography (SPECT), CA, and PCI,. SPECT exposes patients to approximately 6-9 mSv, CA to approximately 2.3-22.7 mSv, HYPERLINK \l "_ENREF_2" \o "Einstein, 2007 #338"  ADDIN EN.CITE <EndNote><Cite><Author>Einstein</Author><Year>2007</Year><RecNum>338</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>338</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="1441095197">338</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Einstein, Andrew J.</author><author>Moser, Kevin W.</author><author>Thompson, Randall C.</author><author>Cerqueira, Manuel D.</author><author>Henzlova, Milena J.</author></authors></contributors><titles><title>Radiation Dose to Patients From Cardiac Diagnostic Imaging</title><secondary-title>Circulation</secondary-title></titles><periodical><full-title>Circulation</full-title></periodical><pages>1290-1305</pages><volume>116</volume><number>11</number><dates><year>2007</year><pub-dates><date>September 11, 2007</date></pub-dates></dates><urls><related-urls><url>http://circ.ahajournals.org/content/116/11/1290.short</url></related-urls></urls><electronic-resource-num>10.1161/circulationaha.107.688101</electronic-resource-num></record></Cite></EndNote>2 and PCI to approximately 7–57 mSV. HYPERLINK \l "_ENREF_3" \o "Picano, 2014 #340"  ADDIN EN.CITE <EndNote><Cite><Author>Picano</Author><Year>2014</Year><RecNum>340</RecNum><DisplayText><style face="superscript">3</style></DisplayText><record><rec-number>340</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="1441095961">340</key></foreign-keys><ref-type name="Book">6</ref-type><contributors><authors><author>Picano, Eugenio</author><author>Vañó, Eliseo</author><author>Rehani, Madan M.</author><author>Cuocolo, Alberto</author><author>Mont, Lluis</author><author>Bodi, Vicente</author><author>Bar, Olivier</author><author>Maccia, Carlo</author><author>Pierard, Luc</author><author>Sicari, Rosa</author><author>Plein, Sven</author><author>Mahrholdt, Heiko</author><author>Lancellotti, Patrizio</author><author>Knuuti, Juhani</author><author>Heidbuchel, Hein</author><author>Di Mario, Carlo</author><author>Badano, Luigi P.</author></authors></contributors><titles><title>The appropriate and justified use of medical radiation in cardiovascular imaging: a position document of the ESC Associations of Cardiovascular Imaging, Percutaneous Cardiovascular Interventions and Electrophysiology</title></titles><pages>665-672</pages><volume>35</volume><number>10</number><dates><year>2014</year><pub-dates><date>2014-03-07 00:00:00</date></pub-dates></dates><work-type>Journal Article</work-type><urls><related-urls><url>http://eurheartj.oxfordjournals.org/ehj/35/10/665.full.pdf</url></related-urls></urls><electronic-resource-num>10.1093/eurheartj/eht394</electronic-resource-num></record></Cite></EndNote>3 An exposure to 10 mSv causes approximately one additional cancer case per 1,000 examinations. 
Cardiac magnetic resonance imaging (CMR) has a high diagnostic accuracy for the detection of CHD. ADDIN EN.CITE ,  The results from the prospective CE-MARC study indicated that CMR has better sensitivity and negative predictive values compared to SPECT for the diagnosis of CHD, with identical specificity. ADDIN EN.CITE ,  CMR is increasingly replacing exercise treadmill testing (ETT) and SPECT, and previous cost-effectiveness studies have shown favourable results in the UK. HYPERLINK \l "_ENREF_7" \o "Walker, 2013 #39"  ADDIN EN.CITE <EndNote><Cite><Author>Walker</Author><Year>2013</Year><RecNum>39</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>39</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="0">39</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walker, Simon</author><author>Girardin, François</author><author>McKenna, Claire</author><author>Ball, Stephen G</author><author>Nixon, Jane</author><author>Plein, Sven</author><author>Greenwood, John P</author><author>Sculpher, Mark</author></authors></contributors><titles><title>Cost-effectiveness of cardiovascular magnetic resonance in the diagnosis of coronary heart disease: an economic evaluation using data from the CE-MARC study</title><secondary-title>Heart</secondary-title></titles><dates><year>2013</year><pub-dates><date>April 16, 2013</date></pub-dates></dates><urls><related-urls><url>http://heart.bmj.com/content/early/2013/04/15/heartjnl-2013-303624.abstract</url></related-urls></urls><electronic-resource-num>10.1136/heartjnl-2013-303624</electronic-resource-num></record></Cite></EndNote>7 In Switzerland, however, the cost-effectiveness of CMR has yet to be demonstrated. We therefore assessed the cost-effectiveness of eight commonly used diagnostic work-up strategies for the diagnosis of CHD from a third-payer perspective in Switzerland.

Methods
Decision model
A decision analytic model developed for the U.K. National Health Service HYPERLINK \l "_ENREF_7" \o "Walker, 2013 #39"  ADDIN EN.CITE <EndNote><Cite><Author>Walker</Author><Year>2013</Year><RecNum>39</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>39</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="0">39</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walker, Simon</author><author>Girardin, François</author><author>McKenna, Claire</author><author>Ball, Stephen G</author><author>Nixon, Jane</author><author>Plein, Sven</author><author>Greenwood, John P</author><author>Sculpher, Mark</author></authors></contributors><titles><title>Cost-effectiveness of cardiovascular magnetic resonance in the diagnosis of coronary heart disease: an economic evaluation using data from the CE-MARC study</title><secondary-title>Heart</secondary-title></titles><dates><year>2013</year><pub-dates><date>April 16, 2013</date></pub-dates></dates><urls><related-urls><url>http://heart.bmj.com/content/early/2013/04/15/heartjnl-2013-303624.abstract</url></related-urls></urls><electronic-resource-num>10.1136/heartjnl-2013-303624</electronic-resource-num></record></Cite></EndNote>7 was adapted to the Swiss context to conduct the cost-effectiveness analysis of eight work-up strategies for the diagnosis of CHD. The work-up strategies included combinations of ETT, SPECT, CMR, and CA (Figure 1). The diagnosis of CHD was modelled using a decision tree, and the occurrence of CV events, depending on the initial diagnosis, was modelled using a Markov state transition model with a 3-month cycle length and a life-time horizon. 
In the decision tree, patients were assigned to one of four states: true positive (TP) for patients who were correctly identified and revascularized, true negative (TN) for those without significant stenosis, false negative (FN) for patients who were misidentified and not revascularized or who died as a result of the mortality risks associated with CA. Because all patients with positive diagnoses were finally referred to CA, which is assumed to be perfectly accurate, no patients were modelled to receive a false positive diagnosis. Revascularization procedures include surgical coronary artery bypass grafting (CABG) and PCI. TP patients who underwent revascularization were assumed to have extra relief from symptoms.
The occurrence of CV events and non-CV deaths among the FN, TN and TP states was quantified by the means of three distinct Markov models. In these Markov models, the risks of CV events and non-CV mortality were determined by four risk equations for angina patients derived from the EUROPA trial. ADDIN EN.CITE 8 The non-CV mortality rates stemmed from Swiss life tables.9 The Markov model also considered radiation exposure during CA, SPECT, and PCI. Further details of the model are described elsewhere. ADDIN EN.CITE 7\o "Walker, 2013 #39" 
Each diagnostic technology can produce positive, negative, or inconclusive results. CA is assumed to be the gold standard; thus, no patient without stenosis underwent revascularization.
The proportion of patients in each state was dependent upon the sensitivities and specificities of the various tests in the diagnostic strategy. Data on the sensitivity and specificity of the diagnostic technologies were obtained from the CE-MARC study ADDIN EN.CITE , \o "Greenwood, 2012 #56" and have been published elsewhere. HYPERLINK \l "_ENREF_7" \o "Walker, 2013 #39"  ADDIN EN.CITE <EndNote><Cite><Author>Walker</Author><Year>2013</Year><RecNum>39</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>39</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="0">39</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walker, Simon</author><author>Girardin, François</author><author>McKenna, Claire</author><author>Ball, Stephen G</author><author>Nixon, Jane</author><author>Plein, Sven</author><author>Greenwood, John P</author><author>Sculpher, Mark</author></authors></contributors><titles><title>Cost-effectiveness of cardiovascular magnetic resonance in the diagnosis of coronary heart disease: an economic evaluation using data from the CE-MARC study</title><secondary-title>Heart</secondary-title></titles><dates><year>2013</year><pub-dates><date>April 16, 2013</date></pub-dates></dates><urls><related-urls><url>http://heart.bmj.com/content/early/2013/04/15/heartjnl-2013-303624.abstract</url></related-urls></urls><electronic-resource-num>10.1136/heartjnl-2013-303624</electronic-resource-num></record></Cite></EndNote>7 All 752 patients who enrolled in the CE-MARC study were randomized to one of two testing sequences including SPECT, CMR and CA. Patients who were considered able to exercise (n=608) underwent ETT independent of the assigned testing sequence. The diagnostic accuracy of each technology is only informed by those patients who could complete it. Although CE-MARC was a single centre study we consider it representative for Switzerland where CMR is conducted predominantly in large university or teaching hospitals which are assumed to adhere to similar quality standards as the CE-MARC study centre. The sensitivities and specificities estimated in the CE-MARC study also correspond well to the receiver operating characteristic (ROC) curves obtained in the MR-IMPACT study which was conducted in 18 centres in Europe and the U.S. including one Swiss centre. HYPERLINK \l "_ENREF_10" \o "Schwitter, 2008 #55"  ADDIN EN.CITE <EndNote><Cite><Author>Schwitter</Author><Year>2008</Year><RecNum>55</RecNum><DisplayText><style face="superscript">10</style></DisplayText><record><rec-number>55</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="0">55</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Schwitter, Juerg</author><author>Wacker, Christian M</author><author>van Rossum, Albert C</author><author>Lombardi, Massimo</author><author>Al-Saadi, Nidal</author><author>Ahlstrom, Hakan</author><author>Dill, Thorsten</author><author>Larsson, Henrik BW</author><author>Flamm, Scott D</author><author>Marquardt, Moritz</author></authors></contributors><titles><title>MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial</title><secondary-title>European heart journal</secondary-title></titles><pages>480-489</pages><volume>29</volume><number>4</number><dates><year>2008</year></dates><isbn>0195-668X</isbn><urls></urls></record></Cite></EndNote>10 The CE-MARC study allows for the consideration of the dependence of the diagnostic accuracy of a diagnostic procedure on the results of the previous diagnostic test included in a work-up strategy. It has been assumed that the time it takes to progress through the different elements of a diagnostic strategy does not differ between strategies. \o "Briggs, 2007 #57"\o "Swiss Federal Office of Statistics, 2014 #38"
Model outcomes are the expected quality-adjusted life-years (QALY) and total medical costs per patient over a life-time horizon from a third-party payer perspective. The health-related quality of life (HRQoL) of each patient is estimated based on the patient's age, gender, initial CCS grade, and treatment status, i.e., whether the patient had received a revascularization procedure or medical management. Future costs and QALYs are discounted at 2.5% per annum.
Analysis
To reflect the uncertainty in the evidence used in the model, the input parameters were entered as probability distributions. A Monte Carlo simulation with 5,000 model runs was used to calculate the mean costs and QALY for each strategy and the probability that a strategy was cost-effective for a given cost-effectiveness threshold.11 Because there are no official thresholds in Switzerland, we transferred the thresholds used by the UK National Institute of Health and Clinical Excellence (NICE) of £20,000 – £30,000 per QALY gained according to gross domestic product values, which results in thresholds of €60,000 – €90,000 in Switzerland. HYPERLINK \l "_ENREF_12" \o "Pletscher, 2013 #11"  ADDIN EN.CITE <EndNote><Cite><Author>Pletscher</Author><Year>2013</Year><RecNum>11</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="zzaeeswduezsf5ee09rpz0v5259rw0xsdd29" timestamp="1443548796">11</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Pletscher, Mark</author><author>Plessow, Rafael</author><author>Eichler, Klaus</author><author>Wieser, Simon</author></authors></contributors><titles><title>Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland</title><secondary-title>Swiss Med Wkly</secondary-title></titles><periodical><full-title>Swiss Med Wkly</full-title></periodical><pages>w13732</pages><volume>143</volume><dates><year>2013</year></dates><urls></urls></record></Cite></EndNote>12 The distributions and measures of variation were obtained from a previous Markov model.7 The cost parameters, which were calculated for the Swiss health care system, were assumed to have Poisson distributions, implying that the variance equals the mean and that the expected value of the cost parameters follows a gamma distribution. 
The sensitivity of the results to changes in the input parameters was assessed in a scenario analysis. We evaluated the effects of changes in patient gender and age, the prevalence of stenosis in the screened population, the angina symptom severity, the cost inputs, and the discount rate on the model results.  The effects of changes in the prevalence of stenosis can give evidence of the effects of different patient populations in the CE-MARC study and in Swiss clinical practice.
\o "Walker, 2013 #39"Population
For the base case population, we considered 60-year-old male patients with chest pain suspected to represent CCS grade 2 with at least one CV risk factor and a 39.5% prior risk of stenosis but without a history of myocardial infarction. If the work-up confirmed the presence of CHD, then the symptoms represented CCS angina grade 2. If a CHD diagnosis was excluded, the chest pain represented non-cardiac chest pain symptoms (e.g., musculoskeletal symptoms or gastro-oesophageal reflux, among others).
The patients' characteristics were derived from the CE-MARC study population, which included 752 patients with suspected stable angina symptoms referred to the Leeds General Infirmary, West Yorkshire, UK. HYPERLINK \l "_ENREF_5" \o "Greenwood, 2012 #56"  ADDIN EN.CITE <EndNote><Cite><Author>Greenwood</Author><Year>2012</Year><RecNum>56</RecNum><DisplayText><style face="superscript">5</style></DisplayText><record><rec-number>56</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="0">56</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Greenwood, John P</author><author>Maredia, Neil</author><author>Younger, John F</author><author>Brown, Julia M</author><author>Nixon, Jane</author><author>Everett, Colin C</author><author>Bijsterveld, Petra</author><author>Ridgway, John P</author><author>Radjenovic, Aleksandra</author><author>Dickinson, Catherine J</author></authors></contributors><titles><title>Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial</title><secondary-title>The Lancet</secondary-title></titles><pages>453-460</pages><volume>379</volume><number>9814</number><dates><year>2012</year></dates><isbn>0140-6736</isbn><urls></urls></record></Cite></EndNote>5 The exclusion criteria in the CE-MARC study were previous CABG, acute coronary syndrome, and chronic renal failure, among others. 
Cost 
The cost inputs were calculated for the Swiss health care system, from a third-party payer perspective, for the year 2012. All costs were calculated in Swiss francs (CHF) and were converted to Euros (€) at the conversion rate of May 28, 2015 of CHF 1 = EUR 0.97. The cost parameters included the costs of diagnostic procedures, the inpatient costs of revascularization, the costs of treatment of CHD risk factors, the acute care costs for fatal and non-fatal CV events, the follow-up costs after adverse CV events, and the acute care costs of non-CV fatal events.​[1]​
The diagnostic procedure costs were derived from a recent Swiss publication HYPERLINK \l "_ENREF_13" \o "Moschetti, 2013 #40"  ADDIN EN.CITE <EndNote><Cite><Author>Moschetti</Author><Year>2013</Year><RecNum>40</RecNum><DisplayText><style face="superscript">13</style></DisplayText><record><rec-number>40</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="0">40</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Moschetti, K</author><author>Muzzarelli, S</author><author>Pinget, C</author><author>Wasserfallen, JB</author><author>Schwitter, J</author><author>Bruder, O</author><author>Schneider, S</author><author>Nothnagel, D</author><author>Pilz, G</author><author>Lombardi, M</author></authors></contributors><titles><title>Cost evaluation of cardiovascular magnetic resonance versus coronary angiography for the diagnostic work-up of coronary artery disease: Application of the European Cardiovascular Magnetic Resonance registry data to the German, United Kingdom, Swiss, and United States health care systems</title><secondary-title>J Cardiovasc Magn Reson</secondary-title></titles><pages>9</pages><volume>15</volume><number>1</number><dates><year>2013</year></dates><urls></urls></record></Cite></EndNote>13 and our own calculations based on the TARMED outpatient tariff system. HYPERLINK \l "_ENREF_14" \o "TARMED Suisse, 2012 #1"  ADDIN EN.CITE <EndNote><Cite><Author>TARMED Suisse</Author><Year>2012</Year><RecNum>1</RecNum><DisplayText><style face="superscript">14</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="0">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>TARMED Suisse,</author></authors></contributors><titles><title>TARMED</title><secondary-title>Tarifversion 1.08</secondary-title></titles><volume>published 14.06.2012 </volume><number>accessed 1.7.2014</number><dates><year>2012</year></dates><urls></urls></record></Cite></EndNote>14 The costs of acute care for CV events were estimated on the basis of SwissDRG per-case payments for inpatient acute care HYPERLINK \l "_ENREF_15" \o "SwissDRG AG, 2012 #41"  ADDIN EN.CITE <EndNote><Cite><Author>SwissDRG AG</Author><Year>2012</Year><RecNum>41</RecNum><DisplayText><style face="superscript">15</style></DisplayText><record><rec-number>41</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="0">41</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>SwissDRG AG,</author></authors></contributors><titles><title>SwissDRG webgrouper</title></titles><number>March 12, 2015</number><dates><year>2012</year></dates><urls><related-urls><url>https://webgrouper.swissdrg.org/de/webgrouper_patient_cases</url></related-urls></urls></record></Cite></EndNote>15 and per-diem rates for inpatient rehabilitation care. HYPERLINK \l "_ENREF_16" \o "tarifsuisse, 2013 #42"  ADDIN EN.CITE <EndNote><Cite><Author>tarifsuisse</Author><Year>2013</Year><RecNum>42</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>42</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="0">42</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>tarifsuisse</author></authors></contributors><titles><title>Inpatient hospital tariffs</title><secondary-title>Solothurn</secondary-title></titles><dates><year>2013</year></dates><urls></urls></record></Cite></EndNote>16 The costs of treatment for CHD risk factors included the costs of outpatient care and medication for diabetes, hypertension, and hyperlipidaemia and were calculated based on published cost studies. ADDIN EN.CITE 17-22
Results
Base case results
In the base case scenario, the cost-effectiveness of the eight diagnostic work-up strategies was assessed for a population of 60-year-old males with suspected CCS grade 2 and a prior likelihood of stenosis of 39.5%. Strategy 7, including a CMR after inconclusive ETT results, was the least costly and most effective strategy and, therefore, dominated the other strategies (Table 2). This diagnostic pathway had a favourable trade-off between false negative diagnoses associated with an elevated risk of CV events and false positive diagnoses leading to unnecessary CA and related mortality. The model results suggested that the use of Strategy 7 instead of the second most effective strategy (Strategy 5) would lead to a gain of 1 QALY per 1,170 screened patients. Assuming a willingness-to-pay of €60,000 for one QALY gained, Strategy 7 is highly likely to be cost-effective with a probability of 99.64%.
Scenario and sensitivity analyses
In the scenario analyses, we assessed the impact of patient characteristics, disease prevalence in the screened population, cost inputs, and discount rate on the cost-effectiveness results (Table 3). The finding that Strategy 7 was strictly dominant was unaffected by changes in patient gender or age, angina symptom severity, ±20% variation in costs of ETT, SPECT, CABG and PCI, acute care and the follow-up costs of CV events, and the discount rate. The finding that even a 20% reduction in the cost of SPECT would not make strategies including SPECT cost-effective has important implications for clinical practice.
Disease prevalence, however, appeared to be an important determinant of the cost-effectiveness of CMR. In a low-risk population (disease prevalence ≤20%), Strategy 3, including a CMR after both positive and inconclusive ETTs, becomes strictly dominant because CMR identified many false positive diagnoses from ETT, which prevented unnecessary CA associated with increased costs, and because ETT removed at least some of the TN patients at a lower cost than immediate CMR. In a high-risk population (disease prevalence ≥60%), however, Strategy 2, including only ETT before CA, was strictly dominant because the risk of false positive ETT diagnoses became smaller than in the base case population and also because the risk of false negative CMR was greater. The results were also sensitive to changes in the costs of CMR and CA. If the costs of CMR increased by 20%, Strategy 7 became more costly than Strategy 2. In this scenario, the incremental cost-effectiveness ratio (ICER) of Strategy 7 compared to Strategy 2 amounts to €27,047 per QALY gained. If the costs of CA decreased by 20%, Strategy 7 became more expensive than Strategy 2 because the cost savings from preventing unnecessary CA decreased. At lower costs of CA, the ICER of Strategy 7 compared to Strategy 2 was €35,338 per QALY gained. 
Discussion
Principal findings
Based on patient characteristics and the diagnostic accuracy of various tests derived from the CE-MARC study, HYPERLINK \l "_ENREF_5" \o "Greenwood, 2012 #56"  ADDIN EN.CITE <EndNote><Cite><Author>Greenwood</Author><Year>2012</Year><RecNum>56</RecNum><DisplayText><style face="superscript">5</style></DisplayText><record><rec-number>56</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="0">56</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Greenwood, John P</author><author>Maredia, Neil</author><author>Younger, John F</author><author>Brown, Julia M</author><author>Nixon, Jane</author><author>Everett, Colin C</author><author>Bijsterveld, Petra</author><author>Ridgway, John P</author><author>Radjenovic, Aleksandra</author><author>Dickinson, Catherine J</author></authors></contributors><titles><title>Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial</title><secondary-title>The Lancet</secondary-title></titles><pages>453-460</pages><volume>379</volume><number>9814</number><dates><year>2012</year></dates><isbn>0140-6736</isbn><urls></urls></record></Cite></EndNote>5 Strategy 7, including CMR after inconclusive ETT, was determined to be the best strategy, i.e., it resulted in the highest QALY gained at the lowest costs compared to all other tested work-up strategies. These findings remained robust to changes in patient age and gender, angina symptom severity, the discount rate, the cost of diagnostic testing (i.e., varying the costs of ETT, SPECT, CABG, and PCI by ±20%), and the costs of cardiovascular events. The prevalence of significant CHD in the investigated population and the costs of CMR and CA, however, appeared to be pivotal determinants of the cost-effectiveness of CMR in Switzerland.
The sensitivity analysis on the pre-test likelihood shows how differences between the CE-MARC cohort and Swiss patients undergoing diagnostic work-up can affect the results of our cost-effectiveness study. If Swiss patients undergoing work-up exhibit a higher prevalence rate of stenosis, e.g. because of differences in risk factors, patient pathways or access to care, the benefits of CMR are expected to be lower in Swiss clinical practice than in the CE-MARC study. Conversely, CMR is expected to perform even better than in the CE-MARC study if the prevalence of stenosis among the investigated patients is low. In the European CMR registry, the prevalence of ischemia-positive patients was 21% HYPERLINK \l "_ENREF_23" \o "Moschetti, 2015 #341"  ADDIN EN.CITE <EndNote><Cite><Author>Moschetti</Author><Year>2015</Year><RecNum>341</RecNum><DisplayText><style face="superscript">23</style></DisplayText><record><rec-number>341</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="1453752434">341</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Moschetti, Karine</author><author>Petersen, Steffen E</author><author>Pilz, Guenter</author><author>Kwong, Raymond Y</author><author>Wasserfallen, Jean-Blaise</author><author>Lombardi, Massimo</author><author>Korosoglou, Grigorios</author><author>Van Rossum, Albert C</author><author>Bruder, Oliver</author><author>Mahrholdt, Heiko</author></authors></contributors><titles><title>Cost-minimization analysis of three decision strategies for cardiac revascularization: results of the “suspected CAD” cohort of the european cardiovascular magnetic resonance registry</title><secondary-title>Journal of Cardiovascular Magnetic Resonance</secondary-title></titles><periodical><full-title>Journal of Cardiovascular Magnetic Resonance</full-title></periodical><pages>1-10</pages><volume>18</volume><number>1</number><dates><year>2015</year></dates><isbn>1532-429X</isbn><urls></urls></record></Cite></EndNote>23 and CAD prevalence among Swiss patients undergoing invasive CA was estimated at 34%. HYPERLINK \l "_ENREF_24" \o "Maeder, 2011 #342"  ADDIN EN.CITE <EndNote><Cite><Author>Maeder</Author><Year>2011</Year><RecNum>342</RecNum><DisplayText><style face="superscript">24</style></DisplayText><record><rec-number>342</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="1453752874">342</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Maeder, M</author></authors></contributors><titles><title>Swiss society of cardiology</title><secondary-title>Cardiovascular Medicine acts</secondary-title></titles><periodical><full-title>Cardiovascular Medicine acts</full-title></periodical><pages>8–10</pages><volume>Basel</volume><number>Abstract</number><dates><year>2011</year></dates><urls></urls></record></Cite></EndNote>24 These results suggest that the disease prevalence in the Swiss patient population undergoing non-invasive testing can be lower than 34%, and that the base case result of this study might even underestimate the benefits of CMR Switzerland. 
Comparison with other studies
The present study produced slightly different conclusions than a previous study evaluating the cost-effectiveness of CMR in the UK. HYPERLINK \l "_ENREF_7" \o "Walker, 2013 #39"  ADDIN EN.CITE <EndNote><Cite><Author>Walker</Author><Year>2013</Year><RecNum>39</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>39</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="0">39</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walker, Simon</author><author>Girardin, François</author><author>McKenna, Claire</author><author>Ball, Stephen G</author><author>Nixon, Jane</author><author>Plein, Sven</author><author>Greenwood, John P</author><author>Sculpher, Mark</author></authors></contributors><titles><title>Cost-effectiveness of cardiovascular magnetic resonance in the diagnosis of coronary heart disease: an economic evaluation using data from the CE-MARC study</title><secondary-title>Heart</secondary-title></titles><dates><year>2013</year><pub-dates><date>April 16, 2013</date></pub-dates></dates><urls><related-urls><url>http://heart.bmj.com/content/early/2013/04/15/heartjnl-2013-303624.abstract</url></related-urls></urls><electronic-resource-num>10.1136/heartjnl-2013-303624</electronic-resource-num></record></Cite></EndNote>7 Whilst Walker et al. concluded that Strategy 3 (ETT followed by CMR if the ETT result is positive or inconclusive and then followed by CA if the CMR result is positive or inconclusive) and Strategy 5 (CMR followed by CA if the CMR result is positive or inconclusive) were the most cost-effective pathways in the UK, our results indicated that Strategy 7 (ETT followed by CA if positive or followed by CMR if the ETT result is inconclusive and then followed by CA if the CMR result is positive) was the most effective and least costly approach, based on healthcare costs in Switzerland. The scenario analysis suggested that the main driver of this difference was the cost difference between CMR and CA. Because the cost difference between CA and CMR is smaller in Switzerland, the avoidance of unnecessary CA after false-positive ETT by using the CMR as an additional test is more efficient in Switzerland than in the UK. Furthermore, exposure to ionizing radiation might be another argument for selecting CMR over CA.
Strengths and limitations
This study provides the first assessment of the cost-effectiveness of various strategies for the diagnosis of CHD in Switzerland. The use of an elaborated Markov simulation model in combination with data from the CE-MARC study HYPERLINK \l "_ENREF_5" \o "Greenwood, 2012 #56"  ADDIN EN.CITE <EndNote><Cite><Author>Greenwood</Author><Year>2012</Year><RecNum>56</RecNum><DisplayText><style face="superscript">5</style></DisplayText><record><rec-number>56</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="0">56</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Greenwood, John P</author><author>Maredia, Neil</author><author>Younger, John F</author><author>Brown, Julia M</author><author>Nixon, Jane</author><author>Everett, Colin C</author><author>Bijsterveld, Petra</author><author>Ridgway, John P</author><author>Radjenovic, Aleksandra</author><author>Dickinson, Catherine J</author></authors></contributors><titles><title>Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial</title><secondary-title>The Lancet</secondary-title></titles><pages>453-460</pages><volume>379</volume><number>9814</number><dates><year>2012</year></dates><isbn>0140-6736</isbn><urls></urls></record></Cite></EndNote>5 has several strengths. First, the CE-MARC study was the largest prospective evaluation of CMR to date and provided sound results of four diagnostic tests across a population of patients (cohort) with suspected angina. Second, the distinction between positive, negative, and inconclusive results increased the meaningfulness of the results for clinical practice in which test results are not always unambiguous. Third, the cost inputs were calculated using Swiss primary data sources and Swiss cost-of-illness studies. The adaptation of a previous Markov model to the Swiss context delivered interesting insights into the determinants of cross-country differences in the cost-effectiveness of different strategies for the diagnosis of CHD. Fourth, the sophistication of the model considered the elevated long-term mortality from ionizing radiation exposure during CA, SPECT, and PCI procedures. HYPERLINK \l "_ENREF_25" \o "Beir, 2006 #22"  ADDIN EN.CITE <EndNote><Cite><Author>Beir</Author><Year>2006</Year><RecNum>22</RecNum><DisplayText><style face="superscript">25</style></DisplayText><record><rec-number>22</rec-number><foreign-keys><key app="EN" db-id="zzaeeswduezsf5ee09rpz0v5259rw0xsdd29" timestamp="1443548797">22</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Beir, V. I. I.</author></authors></contributors><titles><title>Health risks from exposure to low levels of ionizing radiation</title><secondary-title>BEIR VII Phase 2</secondary-title></titles><periodical><full-title>BEIR VII phase 2</full-title></periodical><dates><year>2006</year></dates><urls></urls></record></Cite></EndNote>25
This study has some shortcomings. First, the analysis did not consider technologies that were not included in the CE-MARC study, such as stress echocardiography or computed tomography coronary angiography (CTCA). However, ETT, CMR, and SPECT are the most frequently used technologies for the diagnosis of CHD in Switzerland, and the use of diagnostic accuracy data from a single trial eliminates the risk of a biased comparison due to unadjusted heterogeneity across trials. Second, a comparison of strategies with and without ETT only provides meaningful results for a population of patients with an interpretable resting ECG who are able to exercise and thus can undergo ETT. Third, the CE-MARC study was a single centre study and the results only apply to centres with similar quality standards. It is questionable whether all Swiss CMR centres achieved the same high quality standards as the CE-MARC study site. Fourth, the Markov model simulated the cost-effectiveness for a cohort of one gender and age group with a uniform severity of angina symptoms (i.e., CCS classification); if we applied only one strategy to the population as a whole, we would fail to reflect the benefits from identifiable heterogeneity in the population (i.e., that different strategies will be more cost-effective in different patient groups). ADDIN EN.CITE 26
However, the scenario analyses showed that gender, age, and angina symptom severity did not significantly affect the results. Third, the disutility associated with CV events stemmed from a study evaluating quality-of-life decrements due to various diseases in the UK. HYPERLINK \l "_ENREF_27" \o "Sullivan, 2011 #51"  ADDIN EN.CITE <EndNote><Cite><Author>Sullivan</Author><Year>2011</Year><RecNum>51</RecNum><DisplayText><style face="superscript">27</style></DisplayText><record><rec-number>51</rec-number><foreign-keys><key app="EN" db-id="5wdz522tppadp2ep5a4x9xr0zz0f55d0vsdd" timestamp="0">51</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Sullivan, Patrick W</author><author>Slejko, Julia F</author><author>Sculpher, Mark J</author><author>Ghushchyan, Vahram</author></authors></contributors><titles><title>Catalogue of EQ-5D scores for the United Kingdom</title><secondary-title>Medical Decision Making</secondary-title></titles><pages>800-804</pages><volume>31</volume><number>6</number><dates><year>2011</year></dates><isbn>0272-989X</isbn><urls></urls></record></Cite></EndNote>27 As a result of the Swiss health care system and different treatment approaches, the quality-of-life decrements due to CV events might be different. However, this limitation should not change the basic findings of this study because the QALY decrement due to an event is not expected to affect the ordering of the diagnostic strategies, as tested with the sensitivity analyses.
Implications for clinical practice and policy
The results of this study might have important implications for policy and clinical practice. The cost-effectiveness analysis confirmed the findings from the CE-MARC study that CMR should be more widely used in the work-up of suspected CHD. Strategies including SPECT, however, do not appear to be cost-effective alternatives, even not at 20% lower cost. However, the decision to use CMR depends on the pre-test disease prevalence. In patients with a high risk of CHD, physicians can refer patients with a positive or inconclusive ETT diagnosis directly to CA. In patients with a low risk of CHD, however, CMR should be used after both positive and inconclusive ETT results to avoid unnecessary CA. Because CA is not only associated with additional costs but also with increased mortality, an accurate risk assessment before the diagnosis of CHD has the potential not only to save costs but also to provide clinical benefits by avoiding premature and iatrogenic death.
As the cost-effectiveness results depended on the unit costs of CMR and CA, the current negotiations regarding outpatient tariff rates in Switzerland could affect the cost-effectiveness of CMR in the diagnosis of CHD. If the costs of CA are lowered relative to the costs of CMR, a strategy including CMR might incur higher costs than a diagnosis based on ETT alone. However, the scenario analysis suggested that even with 20% lower CA costs, Strategy 7 might be considered as cost-effective in Switzerland, using a threshold of €60,000 – €90,000 per QALY gained.
In this context, it is noteworthy that all but two work-up strategies analysed in this study were in line with the most recent guidelines on stable CHD, ADDIN EN.CITE ,  which recommend assessing ischemia burden by either non-invasive imaging or invasive fractional flow reserve testing. Only Strategies 1 and 2 were not fully in agreement with these guidelines, as no ischemia testing is integrated in their work-up, which can lead to higher rates of revascularizations. ADDIN EN.CITE ,  Future studies could also evaluate the cost-effectiveness of strategies including CTCA.
In conclusion, CMR was found to be cost-effective in a work-up strategy compared to other diagnostic algorithms using SPECT or direct CA in Switzerland. In patients with suspected angina symptoms and with intermediate risk of CHD, CMR should be more widely recommended as the diagnostic procedure.
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Tables

Table 1: Cost inputs for the Markov model [EUR]
Procedure	Mean	Standard deviationa	Distribution
ETT	220	15	gamma
CMR	1'372	37	gamma
SPECT	2'109	46	gamma
CA	2'492	50	gamma
PCI	9'275	96	gamma
CABG	38'516	196	gamma
Risk factor modification in patients with CHD (per quarter)	193	14	gamma
Acute care for non-fatal cardiovascular event	17'983	134	gamma
Acute care for fatal cardiovascular event	5'957	77	gamma
Acute care for fatal non-cardiovascular event	7'650	87	gamma
Follow-up costs after non-fatal cardiovascular event (per quarter)	453	21	gamma
a: Cost data are assumed to be Poisson distributed			



Table 2: Probabilistic base case cost-effectiveness results
Strategy	Costs [EUR]	QALYs	P[ICER<60,000]	P[ICER<90,000]
Strategy 7	19'663	11.1740	0.9964	0.9970
Strategy 2	19'730	11.1732	0.0036	0.0030
Strategy 3	19'826	11.1730	0.0000	0.0000
Strategy 5	19'875	11.1733	0.0000	0.0000
Strategy 8	19'910	11.1729	0.0000	0.0000
Strategy 1	20'425	11.1710	0.0000	0.0000
Strategy 4	20'474	11.1680	0.0000	0.0000
Strategy 6	20'585	11.1682	0.0000	0.0000
Legend: Costs are reported in Euros [€]; E expected value; P probability; ICER incremental cost-effectiveness ratio



Table 3: Probabilistic cost-effectiveness results from the univariate scenario analysis
 	Strategy	E[costs]	E[QALYs]	ICER
 	 	 	 	 
Base case scenarioa	Strategy 7	19'663	11.1740	dominant
 	 	 	 	 
Gender and age
Male - 50 years	Strategy 7	22'238	14.8642	dominant
Male - 60 years	Strategy 7	19'663	11.1740	dominant
Male - 70 years	Strategy 7	17'607	7.4543	dominant
Female - 50 years	Strategy 7	22'116	16.2311	dominant
Female - 60 years	Strategy 7	19'894	12.4859	dominant
Female - 70 years	Strategy 7	17'910	8.3855	dominant
 	 	 	 	 
Prevalence of stenosis in the screened population
20%	Strategy 3	10'815	11.4671	dominant
60%	Strategy 2	28'795	10.8648	dominant
 	 	 	 	 
Angina symptoms severity
CCS class 1	Strategy 7	19'242	11.3098	dominant
CCS class 3	Strategy 7	19'656	10.7422	dominant
CCS class 4	Strategy 7	19'648	10.8931	dominant
 	 	 	 	 
Low cost scenarios
ETT costs x 0.8	Strategy 7	19'580	11.1774	dominant
SPECT costs x 0.8	Strategy 7	19'659	11.1770	dominant
MRI costs x 0.8	Strategy 7	19'572	11.1778	dominant
CA costs x 0.8	Strategy 2	19'417	11.1786	 
 	Strategy 7	19'448	11.1795	35'338*
CABG costs x 0.8	Strategy 7	18'523	11.1788	dominant
PCI costs x 0.8	Strategy 7	19'201	11.1759	dominant
CV event and follow up costs x 0.8	Strategy 7	19'220	11.1701	dominant
 	 	 	 	 
High cost scenarios
ETT costs x 1.2	Strategy 7	19'709	11.1751	dominant
SPECT costs x 1.2	Strategy 7	19'657	11.1771	dominant
MRI costs x 1.2	Strategy 2	19'736	11.1752	 
 	Strategy 7	19'760	11.1760	27'047*
CA costs x 1.2	Strategy 7	19'879	11.1762	dominant
CABG costs x 1.2	Strategy 7	20'770	11.1712	dominant
PCI costs x 1.2	Strategy 7	20'118	11.1745	dominant
CV event and follow up costs x 1.2	Strategy 7	19'220	11.1701	dominant
 	 	 	 	 
Discount rate
1.50%	Strategy 7	20'990	12.3863	dominant
3.50%	Strategy 7	18'545	10.1412	dominant
a: The base case scenario simulates a cohort of 60-year-old male patients with a 39.5% prevalence of stenosis and CCS class 2 symptom severity. *:ICER if Strategy 7 is implemented instead of Strategy 2
Legend: CCS Canadian Cardiovascular Society grading of angina pectoris.


Figures
Figure 1: Diagnostic strategies


Figure 2: Base case cost-effectiveness results

Legend: The horizontal axis shows the total quality adjusted life-years (QALY) an average patient experiences over the residual lifetime after the diagnosis. The vertical axis shows the total medical costs of the diagnosis and treatment of coronary heart disease (CHD) incurred by an average patient in the screened population.




Composition of total direct medical costs
The total discounted direct medical costs are the lowest with Strategy 7, as it prevents substantial unnecessary CA procedures and subsequent CHD events. Strategy 7 incurs the lowest costs of the initial diagnosis and the third lowest costs of medical care for CHD including the treatment of CV events (Figure 3). 
Figure 3: Composition of discounted total direct medical costs [EUR] over a life-time horizon

Strategies that refer more patients to PCI and CABG incur higher costs of revascularization but lower costs of CHD care (Figure 3). The differences in the total direct medical costs, however, are mainly driven by the costs of the initial diagnosis because the combined costs of CABG, PCI, and CHD care are approximately the same in all strategies (EUR 17'884 - 17'895). 


Supplementary material
Cost input calculation
Diagnostic procedures
The costs of CMR, SPECT, and CA are obtained from a recent Swiss publication.12 The costs of ETT are calculated using TARMED outpatient tariff points13 multiplied by an average value of the tariff point of the EUR (0.84).29 The costs of revascularization are calculated according to the minimum SwissDRG cost weights of inpatient cases undergoing PCI or CABG14 multiplied by the average base rate in Swiss University hospitals of EUR 10’810.15 For the valuation of PCI, the cost weight for an inpatient case undergoing PCI without complications (F57B) minus the decrement for a stay lasting only one night is used (0.858). For the valuation of a CABG procedure, the cost weight for an inpatient case undergoing CABG intervention without complications or additional interventions with an average length of stay of 10.4 days (F32Z) is used (3.563).
The treatment of CHD risk factors 
The cost of treating CHD risk factors includes the costs of outpatient care and medication for diabetes, hypertension, and hyperlipidaemia and is calculated based on published cost studies. The costs from studies published in earlier years are adjusted for inflation in the Swiss health care sector between the year of the study and 2012.16 According to Khot et al.,17 17% of all patients with CHD are affected by diabetes, 43% by hypertension, and 35% by hyperlipidaemia. The cost of diabetes care includes the costs of medication, outpatient consultations, outpatient diagnostic procedures, and laboratory tests obtained from a study on the direct medical costs of diabetes in Switzerland.18 The cost of treating hypertension includes medication19 and one outpatient consultation with a general practitioner (GP) per year.20 The cost of treating hyperlipidaemia includes the cost of statins and the management of hyperlipidaemia according to the guidelines of the European Society of Cardiology.21
Acute care for CV events
The costs of acute care for non-fatal CV events include the costs of inpatient care in acute care and rehabilitation hospitals, ambulance rides, and outpatient consultations before admission to the hospital. Data regarding the frequency of inpatient and outpatient care provided to patients with a non-fatal CV event were obtained from the Swiss Medical Statistics of Hospitals (MedStat). The MedStat is a comprehensive registry of all inpatient cases treated in acute care, rehabilitation, and psychiatric hospitals in Switzerland. The MedStat includes information about the main and secondary diagnoses (International Statistical Classification of Diseases, 10th revision, German modification (ICD-10-GM)), the type of admission, the treatment before admission, and the destination after discharge. Cases with CV events are identified by ICD-10-GM main diagnoses of angina pectoris (I20), acute myocardial infarction (I21), subsequent myocardial infarction within 28 days (I22), complications of myocardial infarction (I23), and other ischemic heart diseases (I24). A unique patient identifier allowed us to identify referrals across hospitals and to build disease episodes from single stays. Readmissions within 30 days are assumed to be continuations of the same disease episode.
Inpatient care in acute care hospitals is valued by SwissDRG tariff rates,14 and inpatient rehabilitation care is valued by the average tariff per inpatient day in Swiss rehabilitation hospitals.30 Ambulance costs are obtained from a Swiss study on the costs of acute coronary syndrome,31 and the average cost per outpatient GP consultation is obtained from a database combining all insurance claims submitted to members of the Swiss association of health insurance companies (Santésuisse).20
The costs of fatal CV events include the costs of patients who die in a hospital and of patients who die outside hospitals. The costs of patients who die in a hospital are estimated as the average tariff payments for inpatient episodes associated with a fatal CV event included in the MedStat. The costs of fatal CV events outside hospitals are calculated as the outpatient tariff payments for medical care for CV-related deaths included in the causes of death statistics32 but not in the MedStat. The causes of death statistics include all fatalities in Switzerland with the cause of death coded as an ICD-10-GM diagnosis code. The costs of fatal CV events include the costs of ambulance rides and inpatient care for patients with a main diagnosis of CV who die in a hospital and the costs of an outpatient GP consultation for patients with a main diagnosis CV who die outside the hospital. 
Fatal non-CV events
The costs of fatal non-CV events include the average costs of initial consultations, ambulance rides, and the inpatient care of all patients with non-CV main diagnoses who died in a Swiss acute care hospital in 2012 and the costs of an outpatient GP consultation for all non-CV deaths that occur outside the hospital. 
Long-term follow-up costs after non-fatal CV events
The follow-up costs after a non-fatal CV event are calculated from a Swiss study on the costs of acute coronary syndrome by Wieser et al.31 The follow-up costs include outpatient rehabilitation after discharge from the hospital, regular outpatient consultations with GPs and cardiologists, regular echocardiography, and life-long medications. The costs of beta blockers and statins are corrected for the proportion of patients who use these drugs for risk factor modification.
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^1	 A detailed description of the cost calculation can be found in the Appendix.
